Department of Neurology, University of Athens, Eginition Hospital, Vas. Sophias Avenue 74, 11528 Athens, Greece.
Muscle Nerve. 2013 Feb;47(2):276-8. doi: 10.1002/mus.23692. Epub 2012 Dec 28.
We aimed to determine the effect of different botulinum toxin-A (BTX-A) dilutions on the treatment efficacy and side effects for amyotrophic lateral sclerosis (ALS) related sialorrhea.
Ten patients were enrolled in the study. BTX-A dilution for Group A was 100 U in 1 ml of saline, whereas the dilution for Group B was 100 U in 2 ml of saline. Both groups received 20 U of BTX-A in each parotid gland, and assessments were made by means of the Drooling Impact Scale, items 1 and 3 of the ALS functional rating scale, and visual analog scales for drooling and swallowing function.
Although both groups exhibited a similar improvement in drooling, Group B had a mild but significant deterioration in bulbar function that was not evident in Group A.
These results suggest that BTX-A has a safer profile when reconstituted with 1 ml instead of 2 ml of saline.
我们旨在确定不同的肉毒杆菌毒素 A（BTX-A）稀释液对肌萎缩侧索硬化症（ALS）相关流涎症的治疗效果和副作用的影响。
本研究纳入了 10 名患者。A 组 BTX-A 稀释液为 1 毫升生理盐水中含有 100U BTX-A，B 组为 2 毫升生理盐水中含有 100U BTX-A。两组患者均在每侧腮腺中接受 20U 的 BTX-A，采用流涎影响量表、ALS 功能评定量表的第 1 项和第 3 项以及流涎和吞咽功能的视觉模拟量表进行评估。
尽管两组患者的流涎症状均有相似的改善，但 B 组的球部功能出现轻微但显著恶化，而 A 组则没有。
这些结果表明，与使用 2 毫升生理盐水相比，用 1 毫升生理盐水重新配制 BTX-A 时安全性更高。
